Who are naphazoline hydrocloride's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Placebo to Prazosin, placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan, eye drops (Phenylephrin), Doxazosin (drug), Norepinephrine (Levophed), Bupivacaine-adrenaline.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/naphazoline-hydrocloride.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

naphazoline hydrocloride — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

naphazoline hydrocloride (naphazoline hydrocloride) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-1 adrenergic agonist. Area: Ophthalmology / Otolaryngology.

phase 3 Alpha-1 adrenergic agonist Alpha-1 adrenergic receptor Ophthalmology / Otolaryngology Small molecule Live · refreshed every 30 min

Target snapshot

naphazoline hydrocloride (naphazoline hydrocloride) — EMS. Naphazoline hydrochloride is an alpha-1 adrenergic agonist that causes vasoconstriction of blood vessels in the eye or nasal passages.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
naphazoline hydrocloride TARGET	naphazoline hydrocloride	EMS	phase 3	Alpha-1 adrenergic agonist	Alpha-1 adrenergic receptor
Placebo to Prazosin	Placebo to Prazosin	Brian J Lipworth	marketed	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor
placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan	placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan	Montefiore Medical Center	marketed	Combination cold and cough remedy	H1 receptor (diphenhydramine); alpha-1 adrenergic receptor (phenylephrine); sigma-1 receptor and NMDA receptor (dextromethorphan)
eye drops (Phenylephrin)	eye drops (Phenylephrin)	Medical University of Graz	marketed	Alpha-1 adrenergic agonist	Alpha-1 adrenergic receptor
Doxazosin (drug)	Doxazosin (drug)	Japan Heart Foundation	marketed	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor
Norepinephrine (Levophed)	Norepinephrine (Levophed)	University of Louisville	marketed	Catecholamine; sympathomimetic amine	Alpha-1 adrenergic receptor; alpha-2 adrenergic receptor; beta-1 adrenergic receptor
Bupivacaine-adrenaline	Bupivacaine-adrenaline	University of Aarhus	marketed	Local anesthetic with vasopressor	Voltage-gated sodium channels; alpha-1 adrenergic receptors (adrenaline component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-1 adrenergic agonist class)

Allergan · 2 drugs in this class
EMS · 1 drug in this class
Institute of Liver and Biliary Sciences, India · 1 drug in this class
Medical University of Graz · 1 drug in this class
Rawalpindi Medical College · 1 drug in this class
Tehran Heart Center · 1 drug in this class
Actavis Inc. · 1 drug in this class
University Tunis El Manar · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). naphazoline hydrocloride — Competitive Intelligence Brief. https://druglandscape.com/ci/naphazoline-hydrocloride. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing